首页> 美国卫生研究院文献>other >RIG-I-Like Receptors as Novel Targets for Pan-Antivirals and Vaccine Adjuvants Against Emerging and Re-Emerging Viral Infections
【2h】

RIG-I-Like Receptors as Novel Targets for Pan-Antivirals and Vaccine Adjuvants Against Emerging and Re-Emerging Viral Infections

机译:RIG-I-like受体作为针对新型抗病毒药和疫苗佐剂的新型靶标可对抗新兴和重新出现的病毒感染

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Emerging and re-emerging viruses pose a significant public health challenge around the world, among which RNA viruses are the cause of many major outbreaks of infectious diseases. As one of the early lines of defense in the human immune system, RIG-I-like receptors (RLRs) play an important role as sentinels to thwart the progression of virus infection. The activation of RLRs leads to an antiviral state in the host cells, which triggers the adaptive arm of immunity and ultimately the clearance of viral infections. Hence, RLRs are promising targets for the development of pan-antivirals and vaccine adjuvants. Here, we discuss the opportunities and challenges of developing RLR agonists into antiviral therapeutic agents and vaccine adjuvants against a broad range of viruses.
机译:新兴和重新出现的病毒在全球范围内构成了重大的公共卫生挑战,其中RNA病毒是导致许多重大传染病暴发的原因。作为人类免疫系统的早期防御手段之一,RIG-I样受体(RLR)作为阻止病毒感染进展的前哨弹起着重要作用。 RLR的激活导致宿主细胞中产生抗病毒状态,从而触发免疫的适应性臂并最终清除病毒感染。因此,RLRs是开发全抗病毒药和疫苗佐剂的有希望的目标。在这里,我们讨论了将RLR激动剂发展为抗病毒治疗剂和针对多种病毒的疫苗佐剂的机遇和挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号